Aurinia Pharmaceuticals Inc. — fact timeline

Aurinia Pharmaceuticals Inc. shareholders approved Non-binding advisory say on pay resolution regarding executive compensation at the 2026-06-03 meeting.

“Proposal 3: Based upon the following votes, the shareholders approved, on a non-binding advisory basis, a “say on pay” resolution regarding the Corporation's executive compensation. Number of Shares Percentage of Votes Cast For Against Abstain Broker Non-Votes For Against Withheld/Abstain 66,398,971 4,315,143 609,384 16,049,987 93.10% 6.05% 0.85%”

Aurinia Pharmaceuticals Inc. shareholders approved Appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm at the 2026-06-03 meeting.

“Proposal 2: Based upon the following votes, the shareholders approved the appointment of PricewaterhouseCoopers LLP, Chartered Professional Accountants, as the Corporation's independent registered public accounting firm until the annual general meeting of shareholders to be held in 2027 or until a successor is appointed. Number of Shares Percentage of Votes Cast For Withhold Broker Non-Votes For Against Withheld/Abstain 77,785,132 9,488,350 3 89.14% 0.00% 10.86%”

Aurinia Pharmaceuticals Inc. shareholders approved Election of Directors at the 2026-06-03 meeting.

“Proposal 1: Based upon the following votes, the shareholders elected Kevin Tang, Jeffrey Bailey, Kathy Goetz, Craig Johnson and Tina S. Nova to serve as members of the Corporation's board of directors until the annual general meeting of shareholders to be held in 2027. Number of Shares Percentage of Votes Cast Nominee For Withheld Broker Non-Votes For Against Withheld/Abstain Kevin Tang 68,889,411 2,434,090 16,049,984 96.59% 0.00% 3.41% Jeffrey Bailey 67,990,723 3,332,778 16,049,984 95.33% 0.00% 4.67% Kathy Goetz 68,840,807 2,482,694 16,049,984 96.52% 0.00% 3.48% Craig Johnson 61,694,786 9,628,715 16,049,984 86.50% 0.00% 13.50% Tina S. Nova 61,972,942 9,350,560 16,049,983 86.89% 0.00% 13.11%”

Aurinia Pharmaceuticals Inc. completed an acquisition involving Kezar Life Sciences, Inc. for $6.955 in cash, plus one contingent value right (closed 2026-05-11).

“On May 8, 2026, Parent completed a tender offer for (i) the acquisition of all of the Company’s outstanding shares of common stock, par value $0.001 per share (the “Common Stock”), by Parent through a tender offer (the “Offer”) for a price per share of the Common Stock of: (A) $6.955 in cash (the “Cash Amount”), payable without interest, plus (B) one contingent value right (a “CVR”) (together with the Cash Amount, the “Offer Price”); and (ii) the merger of Merger Sub with and into the Company (the “Merger”), with the Company surviving the Merger.”

Aurinia Pharmaceuticals Inc. updated its the three months ended March 31, 2026 guidance (reaffirmed).

“Aurinia Pharmaceuticals Inc. (Aurinia or the Company) issued a press release announcing its financial results for the quarter ended March 31, 2026.”

Aurinia Pharmaceuticals Inc. entered into Agreement and Plan of Merger with Kezar Life Sciences, Inc. (effective 2026-03-30).

“On March 30, 2026, Aurinia Pharma U.S., Inc., a Delaware corporation (“Parent”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) by and among Kezar Life Sciences, Inc., a Delaware corporation (the “Company” or “Kezar”), Parent, Aurinia Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub” and together with Parent, the “Buyer Entities”)”

Aurinia Pharmaceuticals Inc.: Effective May 15, 2025, the Company's Bylaw No. 2 was amended to provide shareholders the right to set the number of directors (effective 2025-05-15).

“Pursuant to the operation of the Business Corporations Act (Alberta), effective May 15, 2025 the Company's Bylaw No. 2 (the "Bylaws") were amended to provide shareholders of the Company the right to set the number of directors.”

Aurinia Pharmaceuticals Inc. announced a restructuring with charges of $15 to $19 million affecting the Company (approximately 45%).

“cash equivalents, restricted cash, and investments of $348.7 million as of September 30, 2024 • Anticipates a one-time restructuring charge in the fourth quarter of 2024 of $15 to $19 million and estimates post-restructuring annualized cash-based operating expense savings of more than $40 million • Reiterates 2024 net product revenue guidance range of”

Dr. Robert T. Foster retired as Director at Aurinia Pharmaceuticals Inc..

“the Company also announced that Dr. Robert T. Foster has retired from the Board effective November 5, 2024.”

Craig Johnson was appointed as Director at Aurinia Pharmaceuticals Inc..

“Effective November 7, 2024, Aurinia issued a press release announcing the appointment of Craig Johnson to the Board of Directors of the Company”

Scott Habig was terminated as Chief Commercial Officer at Aurinia Pharmaceuticals Inc..

“Aurinia plans to terminate its employment relationship with Scott Habig.”

Kevin Tang was appointed as Director at Aurinia Pharmaceuticals Inc..

“Effective September 12, 2024, the Board appointed Kevin Tang, President of Tang Capital Management, LLC, a life sciences-focused investment company that he founded in 2002, as member of the Board.”

Brinda Balakrishnan resigned as Director at Aurinia Pharmaceuticals Inc..

“the Board, following the deliberation process outlined in the Company’s Majority Voting Policy, determined (i) to accept the resignations of Dr. Billen, Mr. MacKay-Dunn, and Dr. Balakrishnan, effective September 9, 2024”

R. Hector MacKay-Dunn resigned as Director at Aurinia Pharmaceuticals Inc..

“the Board, following the deliberation process outlined in the Company’s Majority Voting Policy, determined (i) to accept the resignations of Dr. Billen, Mr. MacKay-Dunn, and Dr. Balakrishnan, effective September 9, 2024”

Daniel G. Billen resigned as Director at Aurinia Pharmaceuticals Inc..

“the Board, following the deliberation process outlined in the Company’s Majority Voting Policy, determined (i) to accept the resignations of Dr. Billen, Mr. MacKay-Dunn, and Dr. Balakrishnan, effective September 9, 2024”

Aurinia Pharmaceuticals Inc. reported the quarter ended March 31, 2024 results: revenue $50.3 million. Guidance reaffirmed.

“set forth by specific reference in such filing. --- EX-99.1 (EX-99.1) --- AURINIA PHARMACEUTICALS REPORTS FIRST QUARTER 2024 FINANCIAL AND OPERATIONAL RESULTS • Achieved $50.3 million in total net revenue and $48.1 million in net product revenue for the first quarter of 2024, representing year over year growth of approximately 46% and 40% respectively, and”

Volker Knappertz was terminated as Executive Vice President, Research and Development at Aurinia Pharmaceuticals Inc..

“As part of the restructuring that Aurinia Pharmaceuticals Inc. (Aurinia) announced on February 15, 2024, Aurinia plans to terminate its employment relationship with Dr. Volker Knappertz.”

Aurinia Pharmaceuticals Inc. updated its quarter and year ended December 31, 2023 guidance (reaffirmed).

“On February 15, 2024, Aurinia Pharmaceuticals Inc. (Aurinia) issued a press release announcing its financial results for the quarter and year ended December 31, 2023.”

Aurinia Pharmaceuticals Inc. announced a restructuring with charges of approximately $11 - $15 million affecting AUR200 and AUR300 research and development programs.

“This will result in a one-time charge in the first quarter of 2024 of approximately $11 - $15 million and expected operational cost savings of approximately $50 - $55 million annually, with approximately 75% being recognized in 2024 excluding the one-time restructuring charge in the first quarter of 2024.”

Aurinia Pharmaceuticals Inc. reported fourth quarter and full-year 2023 results: revenue approximately $45 million and $176 million. Guidance initiated.

“AURINIA PROVIDES PRELIMINARY UNAUDITED FOURTH QUARTER AND FULL-YEAR 2023 NET REVENUE RESULTS Preliminary unaudited total net revenue for the fourth quarter and full year 2023 of approximately $45 million and $176 million”

Aurinia Pharmaceuticals Inc. reported nine months ended September 30, 2023 results: revenue $130.4 million.

“Total net revenue was $130.4 million for the nine months ended September 30, 2023”

Aurinia Pharmaceuticals Inc. reported three months ended September 30, 2023 results: revenue $54.5 million.

“Total net revenue was $54.5 million for the three months ended September 30, 2023”

Dr. Robert T. Foster was appointed as Board member at Aurinia Pharmaceuticals Inc..

“In connection with the Cooperation Agreement, Dr. Foster was appointed to the Board, effective September 21, 2023.”

Jeffrey A. Bailey was appointed as Director at Aurinia Pharmaceuticals Inc..

“On August 21, 2023, Aurinia Pharmaceuticals Inc. (the Company) issued a press release announcing the appointments of Dr. Karen Smith and Jeffrey A. Bailey to the Board of Directors of the Company (the Board) effective August 18, 2023.”

Dr. Karen Smith was appointed as Director at Aurinia Pharmaceuticals Inc..

“On August 21, 2023, Aurinia Pharmaceuticals Inc. (the Company) issued a press release announcing the appointments of Dr. Karen Smith and Jeffrey A. Bailey to the Board of Directors of the Company (the Board) effective August 18, 2023.”

Aurinia Pharmaceuticals Inc. reported three and six months ended June 30, 2023 results: revenue $41.5 million. Guidance raised.

“Total net revenue was $41.5 million for the three months ended June 30, 2023”

Joseph P. Hagan resigned as director at Aurinia Pharmaceuticals Inc..

“the Board, following the deliberation process outlined in the Company’s Majority Voting Policy, determined to accept the resignations of Dr. Milne and Mr. Hagan effective June 29, 2023.”

George Milne resigned as director at Aurinia Pharmaceuticals Inc..

“the Board, following the deliberation process outlined in the Company’s Majority Voting Policy, determined to accept the resignations of Dr. Milne and Mr. Hagan effective June 29, 2023.”

Aurinia Pharmaceuticals Inc. shareholders rejected Approval of Amendment to the Equity Incentive Plan at the 2023-05-17 meeting.

“Proposal 4: Based upon the following votes, the shareholders did not approve the Company's Amendment to the Equity Incentive Plan.”

Aurinia Pharmaceuticals Inc. shareholders rejected Non-binding advisory vote on executive compensation (say on pay) at the 2023-05-17 meeting.

“Proposal 3: Based upon the following votes, the shareholders did not approve on a non-binding advisory basis, a "say on pay" resolution regarding the Company's executive compensation.”

Aurinia Pharmaceuticals Inc. shareholders approved Ratification of Appointment of PricewaterhouseCoopers LLP as Independent Registered Public Accounting Firm at the 2023-05-17 meeting.

“Proposal 2: Based upon the following votes, the shareholders approved the appointment of PricewaterhouseCoopers LLP, Chartered Professional Accountants, as the Company's independent registered public accounting firm until the annual general meeting of shareholders to be held in 2024 or until a successor is appointed.”

Aurinia Pharmaceuticals Inc. shareholders approved Election of Directors at the 2023-05-17 meeting.

“Proposal 1: Based upon the following votes, the shareholders elected Dr. George Milne, Mr. Peter Greenleaf, Dr. David R.W. Jayne, Mr. Joseph P. Hagan, Dr. Daniel Billen, Mr. R. Hector MacKay-Dunn, Ms. Jill Leversage, and Dr. Brinda Balakrishnan to serve as members of the Company's board of directors until the annual general meeting of shareholders to be held in 2024.”

Aurinia Pharmaceuticals Inc. reported first quarter ended March 31, 2023 results: revenue $34.4 million, net income $26.2 million or $0.18 net loss per common share, EPS $0.18 net loss per common share. Guidance raised.

“as expressly set forth by specific reference in such filing. --- EX-99.1 (EX-99.1) --- AURINIA PHARMACEUTICALS REPORTS FIRST QUARTER 2023 FINANCIAL AND OPERATIONAL RESULTS $34.4 million in net revenue for the first quarter of 2023; an increase of 59% over the first quarter of the prior year Increases 2023 revenue guidance range to $135 - $155 million from net”

Aurinia Pharmaceuticals Inc. reported the quarter and year ended December 31, 2022 results: revenue $28.4 million. Guidance reaffirmed.

“filing. --- EX-99.1 (EX-99.1 PRESS RELEASE) --- PRESS RELEASE Document Exhibit 99.1 AURINIA REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS AND COMPANY UPDATES $28.4 million in total net revenue for the fourth quarter 2022, a 21% increase over fourth quarter 2021 and $134.0 million for full year 2022, a 194% increase over 2021 Cash, cash equivalents,”

Aurinia Pharmaceuticals Inc. reported fourth quarter and full-year 2022 results: revenue approximately $28.4 million and $134.0 million. Guidance reaffirmed.

“Preliminary unaudited net revenue for the fourth quarter and full year 2022 of approximately $28.4 million and $134.0 million”

Aurinia Pharmaceuticals Inc. updated its 2023 guidance (initiated).

“We are also providing preliminary net revenue guidance from product sales of LUPKYNIS for 2023 in the range of $120-140 million”

Aurinia Pharmaceuticals Inc. updated its 2022 guidance (lowered).

“we are adjusting our net revenue guidance to $100-105 million from sales of LUPKYNIS for 2022”

Aurinia Pharmaceuticals Inc. reported the three months ended September 30, 2022 results: revenue $55.8 million.

“set forth by specific reference in such filing. --- EX-99.1 (EX-99.1) --- AURINIA REPORTS THIRD QUARTER AND NINE MONTHS 2022 FINANCIAL AND OPERATIONAL RESULTS Net revenue of $55.8 million for Q3 2022; including $30.0 million milestone from Otsuka related to European Approval of LUPKYNIS ® (voclosporin) Adjusts net product revenue guidance to $100-105 million from”

Neil Solomons resigned as Chief Medical Officer at Aurinia Pharmaceuticals Inc..

“On October 17, 2022, Aurinia Pharmaceuticals Inc. and Robert Huizinga, PhD RN, CNeph(C), our Executive Vice President, Research and Neil Solomons, M.D., our Chief Medical Officer, mutually agreed that Dr. Huizinga and Dr. Solomons would cease their employment with Aurinia, each effective October 31, 2022.”

Robert Huizinga resigned as Executive Vice President, Research at Aurinia Pharmaceuticals Inc..

“On October 17, 2022, Aurinia Pharmaceuticals Inc. and Robert Huizinga, PhD RN, CNeph(C), our Executive Vice President, Research and Neil Solomons, M.D., our Chief Medical Officer, mutually agreed that Dr. Huizinga and Dr. Solomons would cease their employment with Aurinia, each effective October 31, 2022.”

Timothy P. Walbert resigned as Director at Aurinia Pharmaceuticals Inc..

“On September 19, 2022, Timothy P. Walbert, a member of the board of directors (the Board) of Aurinia, notified the Company of his intent to resign from the Board, effective at the close of business on September 19, 2022.”

Max Colao departed as Chief Commercial Officer at Aurinia Pharmaceuticals Inc..

“On July 11, 2022, Aurinia Pharmaceuticals Inc. and Max Colao, our Chief Commercial Officer, mutually agreed that Mr. Colao would cease his employment with Aurinia, effective July 22, 2022.”